gms | German Medical Science

GMS Infectious Diseases

Paul-Ehrlich-Gesellschaft für Infektionstherapie e.V. (PEG) (PEG)

ISSN 2195-8831

Calculated initial parenteral treatment of bacterial infections: Bacterial endocarditis

Guideline Calculated parenteral initial therapy

  • corresponding author Pascal M. Dohmen - Klinik und Poliklinik für Herzchirurgie, Universitätsmedizin Rostock, Germany
  • Klaus Friedrich Bodmann - Klinik für Internistische Intensiv- und Notfallmedizin und Klinische Infektiologie, Klinikum Barnim GmbH, Werner Forßmann Krankenhaus, Eberswalde, Germany
  • Wolfgang Graninger - Vienna, Austria
  • Pramod Shah - Frankfurt am Main, Germany
  • Florian Thallhammer - Klinische Abteilung für Infektiologie und Tropenmedizin, Medizinische Universität Wien, Vienna, Austria

GMS Infect Dis 2020;8:Doc08

doi: 10.3205/id000052, urn:nbn:de:0183-id0000522

This is the English version of the article.
The German version can be found at: http://www.egms.de/de/journals/id/2020-8/id000052.shtml

Published: March 26, 2020

© 2020 Dohmen et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.


Abstract

This is the twelfth chapter of the guideline “Calculated initial parenteral treatment of bacterial infections in adults – update 2018” in the 2nd updated version. The German guideline by the Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (PEG) has been translated to address an international audience.

The bacterial endocarditis is characterised by a constant incidence but a shift in the patient population due to the use of prosthetic heart valves and foreign materials like pacemakers and the increasing application of invasive medical procedures. This is linked to a change in the predominant infecting organisms towards staphylococci. This chapter gives recommendations for the interdisciplinary management of infective endocarditis from the diagnostic workup over prevention to therapy with a focus on antibiotic therapy.


Introduction

Bacterial endocarditis was first mentioned in the 17th century by Morgagni [1]. The aetiology of this infection was only described 100 years later by Rokitansky. It identified bacteria which existed within embolized vegetation [2]. Today, bacterial endocarditis continues to be a disease with significant morbidity and mortality, although antimicrobial and surgical intervention has improved substantially [3]. The incidence of bacterial endocarditis is 1 case per 1,000 hospitalizations in internal medicine [4].

The annual incidence of bacterial endocarditis of native heart valves in Europe is around 3 cases per 100,000 inhabitants [5]. As several studies have shown, the incidence of bacterial endocarditis has remained almost constant in recent decades [6]; this is due to a redistribution of predisposing factors. A systematic review from several Western European countries showed a significant increase in patients with prosthetic heart endocarditis and endocarditis due to degenerative heart valve disease or intravenous drug abuse [7]. The increase in invasive medical procedures has increased the number of bacteremias and thus the proportion of bacterial healthcare-associated endocarditis [8]. This increase of up to 34% in all endocarditis cases [9] also results in the average age increasing 10–15 years in recent years [10], [11].


The hospital setting

A major problem is the long delay between the first occurrence of unrecognized symptoms and the onset of microbial invasion of the endocardium in intravascularly implanted foreign body materials such as heart valve prostheses, pacemaker electrodes, micra cardiocapsules, occluders, and artificial hearts. In Germany in particular, culture-negative endocarditis is common, further complicating definitive diagnosis. The resulting delay to initiating of adequate antibiotic treatment can significantly increase morbidity and mortality [12]. Classic guiding symptoms are often difficult to assess, such as a heart murmur in a patient who has not previously been examined by a cardiologist or non-specific symptoms such as sub-febrile temperature, fever, night sweats, weight loss, loss of appetite, general fatigue, myalgias and arthralgias. Not infrequently, initial symptoms are already signs of incipient complications, such as progressive stress dyspnoea and subsequent orthopnea, which indicates valve destruction with loss of valve function due to a heart valve insufficiency with significant volume overload. Signs of central septic embolization may be the first symptoms of neurological deficits. Right-sided endocarditis may cause symptoms of pulmonary embolization. Furthermore, peripheral micro- or macroemboli may be present in combination with immunological phenomena, for example Osler nodules, Jayneway lesions and splinter hemorrhages.

If risk factors are present, such as intravenous drug abuse or in patients with intravascular implants made from foreign materials, when carrying out a differential diagnosis bacterial endocarditis must always be a consideration, even with non-specific symptoms. For clinical evaluation, the modified Duke criteria should always be used in these patients [13] and, if appropriate, a team of endocarditis experts from a nearby hospital providing maximal medical care should be included [14].


Prevention

Since bacterial endocarditis is a dangerous and difficult-to-treat bacterial infection, endocarditis prophylaxis has been used in risk patients for over 50 years. In 2002, the indications for such prophylactic care were redefined as part of a risk-benefit analysis [15]. These results have been successively incorporated into all international guidelines in recent years [16], [17], [18], [19], [20].

The 2007 American Heart Association guidelines [16] implemented the new indications for endocarditis prophylaxis [21]. The decisive factor was that nowadays such guidance relies exclusively on evidence-based data. Previously the guidelines were based on animal studies and expert opinions, rather than prospective, randomized and double-blind studies as one would expect today. Due to the changes to the indication of endocarditis prophylaxis, it is now only performed in patients at the highest risk of bacterial endocarditis.

In 2008, the National Institute for Health and Care Excellence (NICE) recommended refraining from endocarditis prophylaxis for both dental and non-dental patients [22]. An epidemiological study in the UK conducted following this recommendation showed an increase in the number of bacterial endocarditis cases after the NICE guidelines came into force in 2008 [23]. A survey conducted in the UK in 2012 found that the majority of cardiologists and cardiac surgeons advocated the need for antibiotic prophylaxis in patients with heart valve prostheses [24]. Another UK study showed a significant increase in the incidence of bacterial endocarditis in both high-risk and low-risk patients, so the introduction of NICE guidelines in 2008 cannot be taken as the sole cause of this fact [8].


Interdisciplinary care

The interdisciplinary treatment of patients with bacterial endocarditis begins with good communication between the referring GP and the hospital doctor in charge of admission. The interdisciplinary approach must be continued within the hospital.

The prerequisite for including a patient in the SYNTAX multicentre randomized study, which looked at patients with coronary heart disease, was interdisciplinary collaboration between cardiologists and cardiac surgeons [25]. This concept of a multidisciplinary cardiac team to determine the course of treatment has been adopted for highest-risk patients suffering from aortic valve disease. In such cases, an interdisciplinary team determines which patient will receive conventional surgical aortic valve replacement and which patient will be sent for transcatheter aortic valve implantation (TAVI). This team, consisting of cardiologists and cardiac surgeons, has been expanded to include an anesthesiologist [26]. This concept today is an integral part of European guidelines.

Up until now, cardiology guidelines for treating patients with bacterial endocarditis required an interdisciplinary team of physicians including cardiologists, microbiologists, infectiologists and cardiac surgeons. Due to the complexity of this condition, there was a call for additional experts to be consulted, such as neurologists, neurosurgeons, radiologists, nuclear medicine specialists and anesthesiologists, as well as clinical pharmacologists and in the case of congenital disorders, pediatric cardiologists and pediatric cardiac surgeons. The introduction of these measures has significantly reduced the mortality of endocarditis from 18.5% to 8.2% in a French study [27]. The survival of patients with bacterial endocarditis has been significantly improved elsewhere too by adopting this concept [28]. In 2014, these guidelines were also incorporated into the Guidelines for the Treatment of Patients with Heart Valve Disease [19] by the American Heart Association/American College of Cardiology with a class 1b recommendation. The European Society of Cardiology complied with these guidelines when preparing the ESC guidelines for the treatment of patients with bacterial endocarditis published in 2015 [29].


Imaging

The core diagnostic imaging procedure in transthoracic and, above all, in transesophageal examinations is echocardiography. This examination method is of great importance for pre-operative diagnosis, for pre-operative monitoring, for evaluating the outcome of surgery as well as for post-operative follow-up. However, due to the complexity of today’s endocarditis with an increase in healthcare-associated bacterial endocarditis, additional imaging techniques are needed, such as magnetic resonance imaging, multislice computed tomography or nuclear medical techniques such as single-photon emission tomography (SPECT) and 18F-fluorodeoxyglucose (FDG) positron emission tomography. The necessity of echocardiography as a core examination has already been pointed out. It occupies a key position in terms of diagnosis and assessment. Transesophageal echocardiography is significantly superior in sensitivity to transthoracic echocardiography [30], [31], especially when tricuspid and pulmonary valves in implanted foreign body materials are concerned. However, with respect to florid endocarditis, the specificity of echocardiography is limited [32]. In the presence of clinically suspicious factors however, for example an unclear fever with positive blood cultures in which typical pathogens have been detected, clarification including an echocardiographic examination is absolutely necessary. If active endocarditis is detected, weekly echocardiographic follow-up is useful.

Advanced imaging procedures as described above are of increasing importance in view of the percentage increase in positive blood cultures due to the increasing implementation of foreign materials in patients through invasive procedures and the more and more frequently performed less invasive TAVIs. Studies have shown, for example, that cerebral septic embolisms occur in 33% of patients with endocarditis without clinical symptoms [33]. This fact only became clear through the use of advanced imaging methods.


Pathogen detection

Proof of the causative pathogen is crucial for rapid and targeted treatment. Correctly obtaining at least three blood culture pairs (aerobic and anaerobic) at different times via peripheral venipuncture, with strict adherence to the aseptic conditions for venipuncture and removal of the sample, is of paramount importance. Venous blood cultures are superior to arterial cultures due to fluid dynamic factors.

Because bacterial endocarditis constitutes a continuous bacteremia, blood cultures can be obtained at any time without the need for taking body temperature into account. It is important to note that fever peaks, caused by decomposition of pathogens, represent an unfavorable time for obtaining blood cultures because pathogen density in the blood is particularly low at this point in time. The obtained blood cultures must be immediately forwarded to a microbiological lab.

In up to 30% of cases, pathogens cannot be identified in blood cultures, often due to antibiotic treatment before cultures are obtained. In patients with endocarditis and negative blood cultures who are not critically ill, antibiotic treatment should be interrupted for a period of 48 hours in order to improve conditions for detecting pathogens in a subsequent blood culture. Another cause of negative blood cultures may be the presence of difficult-to-cultivate pathogens such as Bartonella spp., Coxiella spp., Mycoplasma spp., Chlamydia spp., Tropheryma whipplei, fungi and HACEK group pathogens. The HACEK group includes Haemophilus spp., Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens and Kingella spp. It is important to inform the microbiological lab if endocarditis is suspected in order to ensure an adequate examination of the materials. Currently there are culture-independent techniques for the optimization of microbiological diagnostics through application of molecular biological and serological methods. Fluorescence in-situ hybridization (FISH) combines molecular biology and histological techniques, which may also be helpful in detecting pathogens. Biopsies of heart valves, heart valve prostheses or peripheral embolisms can also help to detect pathogens in addition to the polymerase chain reaction (PCR) based on whole blood or serum. Due to a lack of standardization, the relevance of these methods is still unclear.

In addition, the sonication of prostheses, i.e. cardiac pacemakers or heart valves, can increase the detection of pathogens by 30%.


Antimicrobial therapy

If the general condition of a patient is critical, empirical antibiotic treatment is started immediately but always after obtaining blood cultures. For native valve endocarditis and late endocarditis following heart valve replacement (>1 year after surgery or intervention), above all methicillin-sensitive Staphylococcus aureus strains (MSSA), various streptococcal species and Enterococcus faecalis should be expected (Table 1 [Tab. 1]). The microbiological results from the first infection episode may help inform further calculated antimicrobial treatment. However, in early endocarditis after heart valve replacement (<1 year after intervention or surgery) this is more likely to be associated with methicillin-resistant Staphylococcus aureus strains (MRSA), coagulase-negative staphylococci and also Gram-negative bacteria. Initial empirical treatment should, if possible, be modified once microbiological results are available. Treatment schemes for the most common endocarditis agents can be found in Table 2 [Tab. 2]. Further detailed treatment recommendations as well as recommendations regarding complications indicating a need for surgical intervention and for the continuation of antibiotic treatment after surgical restoration can be found in the guidelines of the European Society of Cardiology [29].


Evaluation of Recommendations for Antibiotic Treatment of Endocarditis by the European Society of Cardiology (ESC) 2015

Significant changes to the European guidelines include endocarditis prophylaxis, the interdisciplinary “endocarditis team”, the expansion of imaging modes and the results of a first randomized study on the surgical treatment of bacterial endocarditis.

The European guidelines continue to recommend antibiotic prophylaxis for risky interventions in patients with predisposing cardiac factors. Preliminary studies support this approach, as after the introduction of the NICE guidelines in 2008 [21] negative effects had been shown by the extreme restriction of the indication of antibiotic prophylaxis in the United Kingdom [23], [24].

The recommendation to empirically treat with ampicillin and flucloxacillin in native valve endocarditis does not result from study data but from the need to cover staphylococci, streptococci and Enterococcus faecalis in initial treatment. Because ampicillin/sulbactam is not available in all European countries for parenteral treatment and the combination of amoxicillin/clavulanic acid cannot be dosed adequately for toxicity reasons, the combination of aminopenicillin plus flucloxacillin was recommended. Since ampicillin/sulbactam is available for parenteral treatment in Germany, 4x 3 g of ampicillin/sulbactam would be an equivalent alternative, which has the advantage of having to deal with only one drug or a fixed combination.


Surgical treatment and aftercare

The introduction of interdisciplinary endocarditis teams has shown that surgical treatment is an integral part of the overall treatment concept in bacterial endocarditis and should not only take place once antibiotic treatment has failed. The classic indications for surgical restoration which must be used in approximately 50% of all patients are the development of cardiac insufficiency, irreversible and infection-related destruction of cardiac structures and the appearance of emboli, newly-emergent AV blockages and endocarditis in heart valve prostheses, transcatheter heart valves, pacemaker systems and closure systems. The scores necessary for surgical risk stratification (EuroSCORE II and STS score) are of limited suitability in this, as they were primarily developed for coronary revascularization or degenerative heart valve replacement. For surgical intervention in bacterial endocarditis, special score systems have been developed, such as the De-Feo Score and the International Collaboration on Endocarditis Score (ICE Score).

The advantage of early surgical restoration is that especially in native mitral or tricuspid valve endocarditis, heart valves can be operated on, possibly even in minimally invasive ways. Determining indication for early surgical restoration is often difficult and an important task for the “interdisciplinary endocarditis team”. A randomized study in a low-risk population with small case numbers showed that surgical intervention reduced the rate of embolism significantly within 48 hours up to 6 months after surgery. However, patient survival was unaffected.

Patients who are provided with TAVI represent a special patient population. In order to be able to optimally treat these patients in the future, new strategies must be developed.

The basic principle of surgical restoration is the complete removal of the infectious material and tissue in order to cure the patient’s endocarditis with adequate antibiotic treatment. In Austria, adequate antibiotic treatment is partly carried out as out-patient parenteral antibiotic therapy (OPAT). In Germany, this form of treatment has not yet made inroads.

Imaging techniques (such as echocardiography), blood cultures and serological examinations should serve to monitor treatment success and, if necessary, contribute to appropriate adjustment of therapeutic measures.


Note

This is the twelfth chapter of the guideline “Calculated initial parenteral treatment of bacterial infections in adults – update 2018” in the 2nd updated version. The German guideline by the Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (PEG) has been translated to address an international audience.

Following the publication of the 1st version of the guideline in German, these dosage suggestions were updated by the working group (Table 1: Empiric therapy of culture-negative bacterial endocarditis with previous antibiotic therapy or until the blood culture results are obtained):

  • gentamicin dosage in combination with ampicillin, ampicillin/sulbactam or vancomycin: 1x 3 mg/kg INSTEAD OF 3x 3mg/kg
  • rifampicin dosage in combination with vancomycin: rifampicin 900 mg iv (2 SD) INSTEAD OF rifampicin 900 mg iv (3 SD)

Competing interests

The authors declare that they have no competing interests.


References

1.
Glynn TR. The Mumleian Lectures on Infective endocarditis mainly in its clinical aspects. Lancet. 1903;161(4155):1073-7. DOI: 10.1016/S0140-6736(01) 71890-9 External link
2.
Kirkes WS. On some of the principal effects resulting from the Detachment of Fibrinous Deposits from the interior of the heart, and their mixture with the circulating blood. Med Chir Trans. 1852;35:281-324.
3.
Krul MM, Vonk AB, Cornel JH. Trends in incidence of infective endocarditis at the Medical Center of Alkmaar. Neth Heart J. 2015 Nov;23(11):548-54. DOI: 10.1007/s12471-015-0743-0 External link
4.
Tauchnitz C. Mikrobielle (bakterielle) Endokarditis. In: Hahn H, Falke D, Kaufmann SHE, Ullmann U, editors. Medizinische Mikrobiologie und Infektiologie. Berlin-Heidelberg: Springer; 2005. p. 911-5. DOI: 10.1007/3-540-26529-5_113 External link
5.
Hoen B, Alla F, Selton-Suty C, Béguinot I, Bouvet A, Briançon S, Casalta JP, Danchin N, Delahaye F, Etienne J, Le Moing V, Leport C, Mainardi JL, Ruimy R, Vandenesch F; Association pour l’Etude et la Prévention de l’Endocardite Infectieuse (AEPEI) Study Group. Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA. 2002 Jul;288(1):75-81. DOI: 10.1001/jama.288.1.75 External link
6.
Mathew J, Addai T, Anand A, Morrobel A, Maheshwari P, Freels S. Clinical features, site of involvement, bacteriologic findings, and outcome of infective endocarditis in intravenous drug users. Arch Intern Med. 1995 Aug 7-21;155(15):1641-8. DOI: 10.1001/archinte.1995.00430150125013 External link
7.
Tleyjeh IM, Abdel-Latif A, Rahbi H, Scott CG, Bailey KR, Steckelberg JM, Wilson WR, Baddour LM. A systematic review of population-based studies of infective endocarditis. Chest. 2007 Sep;132(3):1025-35. DOI: 10.1378/chest.06-2048 External link
8.
Benito N, Pericas JM, Gurguí M, Mestres CA, Marco F, Moreno A, Horcajada JP, Miró JM. Health Care-Associated Infective Endocarditis: a Growing Entity that Can Be Prevented. Curr Infect Dis Rep. 2014 Nov;16(11):439. DOI: 10.1007/s11908-014-0439-4 External link
9.
Benito N, Miró JM, de Lazzari E, Cabell CH, del Río A, Altclas J, Commerford P, Delahaye F, Dragulescu S, Giamarellou H, Habib G, Kamarulzaman A, Kumar AS, Nacinovich FM, Suter F, Tribouilloy C, Venugopal K, Moreno A, Fowler VG Jr; ICE-PCS (International Collaboration on Endocarditis Prospective Cohort Study) Investigators. Health care-associated native valve endocarditis: importance of non-nosocomial acquisition. Ann Intern Med. 2009 May;150(9):586-94. DOI: 10.7326/0003-4819-150-9-200905050-00004 External link
10.
Lomas JM, Martínez-Marcos FJ, Plata A, Ivanova R, Gálvez J, Ruiz J, Reguera JM, Noureddine M, de la Torre J, de Alarcón A; Grupo Andaluz para el Estudio de las Infecciones Cardiovasculares (Andalusian Group for the Study of Cardiovascular Infections) at the Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Healthcare-associated infective endocarditis: an undesirable effect of healthcare universalization. Clin Microbiol Infect. 2010 Nov;16(11):1683-90. DOI: 10.1111/j.1469-0691.2009.03043.x External link
11.
DeSimone DC, Tleyjeh IM, Correa de Sa DD, Anavekar NS, Lahr BD, Sohail MR, Steckelberg JM, Wilson WR, Baddour LM. Temporal trends in infective endocarditis epidemiology from 2007 to 2013 in Olmsted County, MN. Am Heart J. 2015 Oct;170(4):830-6. DOI: 10.1016/j.ahj.2015.07.007 External link
12.
Westphal N, Plicht B, Naber C. Infective endocarditis – prophylaxis, diagnostic criteria, and treatment. Dtsch Arztebl Int. 2009 Jul;106(28-29):481-9; quiz 490. DOI: 10.3238/arztebl.2009.0481 External link
13.
Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, Bashore T, Corey GR. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000 Apr;30(4):633-8. DOI: 10.1086/313753 External link
14.
Botelho-Nevers E, Thuny F, Casalta JP, Richet H, Gouriet F, Collart F, Riberi A, Habib G, Raoult D. Dramatic reduction in infective endocarditis-related mortality with a management-based approach. Arch Intern Med. 2009 Jul;169(14):1290-8. DOI: 10.1001/archinternmed.2009.192 External link
15.
Danchin N, Duval X, Leport C. Prophylaxis of infective endocarditis: French recommendations 2002. Heart. 2005; 91(6):715-8. DOI: 10.1136/hrt.2003.033183 External link
16.
Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, Bolger A, Cabell CH, Takahashi M, Baltimore RS, Newburger JW, Strom BL, Tani LY, Gerber M, Bonow RO, Pallasch T, Shulman ST, Rowley AH, Burns JC, Ferrieri P, Gardner T, Goff D, Durack DT; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007 Oct;116(15):1736-54. DOI: 10.1161/CIRCULATIONAHA.106.183095 External link
17.
Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I, Moreillon P, de Jesus Antunes M, Thilen U, Lekakis J, Lengyel M, Müller L, Naber CK, Nihoyannopoulos P, Moritz A, Zamorano JL; ESC Committee for Practice Guidelines. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J. 2009 Oct;30(19):2369-413. DOI: 10.1093/eurheartj/ehp285 External link
18.
Gould FK, Elliott TS, Foweraker J, Fulford M, Perry JD, Roberts GJ, Sandoe JA, Watkin RW; Working Party of the British Society for Antimicrobial Chemotherapy. Guidelines for the prevention of endocarditis: report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother. 2006 06;57(6):1035-42. DOI: 10.1093/jac/dkl121 External link
19.
Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, O’Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM 3rd, Thomas JD, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Creager MA, Curtis LH, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Stevenson WG, Yancy CW; American College of Cardiology; American College of Cardiology/American Heart Association; American Heart Association. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2014 Jul;148(1):e1-e132. DOI: 10.1016/j.jtcvs.2014.05.014 External link
20.
Naber CK; Paul-Ehrlich-Gesellschaft für Chemotherapie; Deutsche Gesellschaft für Kardiologie, Herz- und Kreislaufforschung; Deutsche Gesellschaft für Thorax-, Herz- und Gefässchirurgie; Deutsche Gesellschaft für Infektiologie; Deutsche Gesellschaft für Internistische Intensivmedizin und Notfallmedizin; Deutsche Gesellschaft für Hygiene und Mikrobiologie. S2-Leitlinie zur Diagnostik und Therapie der infektiösen Endokarditis [S2 Guideline for diagnosis and therapy of infectious endocarditis]. Z Kardiol. 2004 Dec;93(12):1005-21. DOI: 10.1007/s00392-004-0183-0 External link
21.
Duval X, Leport C. Prophylaxis of infective endocarditis: current tendencies, continuing controversies. Lancet Infect Dis. 2008 Apr;8(4):225-32. DOI: 10.1016/S1473-3099(08) 70064-1 External link
22.
Centre for Clinical Practice at NICE. Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures. London: National Institute for Health and Clinical Excellence; 2008. (NICE clinical guideline; 64). Available from: https://www.nice.org.uk/guidance/cg64/evidence/full-guideline-pdf-196759981 External link
23.
Thornhill MH, Dayer MJ, Forde JM, Corey GR, Chu VH, Couper DJ, Lockhart PB. Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. BMJ. 2011 May;342:d2392. DOI: 10.1136/bmj.d2392 External link
24.
Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB, Thornhill MH. Incidence of infective endocarditis in England, 2000-13: a secular trend, interrupted time-series analysis. Lancet. 2015 Mar 28;385(9974):1219-28. DOI: 10.1016/S0140-6736(14) 62007-9 External link
25.
Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Ståhle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009 Mar;360(10):961-72. DOI: 10.1056/NEJMoa0804626 External link
26.
Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS); Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Iung B, Lancellotti P, Pierard L, Price S, Schäfers HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012 Oct;33(19):2451-96. DOI: 10.1093/eurheartj/ehs109 External link
27.
Botelho-Nevers E, Thuny F, Casalta JP, Richet H, Gouriet F, Collart F, Riberi A, Habib G, Raoult D. Dramatic reduction in infective endocarditis-related mortality with a management-based approach. Arch Intern Med. 2009 Jul;169(14):1290-8. DOI: 10.1001/archinternmed.2009.192 External link
28.
Chirillo F, Scotton P, Rocco F, Rigoli R, Borsatto F, Pedrocco A, De Leo A, Minniti G, Polesel E, Olivari Z. Impact of a multidisciplinary management strategy on the outcome of patients with native valve infective endocarditis. Am J Cardiol. 2013 Oct;112(8):1171-6. DOI: 10.1016/j.amjcard.2013.05.060 External link
29.
Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, Dulgheru R, El Khoury G, Erba PA, Iung B, Miro JM, Mulder BJ, Plonska-Gosciniak E, Price S, Roos-Hesselink J, Snygg-Martin U, Thuny F, Tornos Mas P, Vilacosta I, Zamorano JL; Document ReviewersErol Ç, Nihoyannopoulos P, Aboyans V, Agewall S, Athanassopoulos G, Aytekin S, Benzer W, Bueno H, Broekhuizen L, Carerj S, Cosyns B, De Backer J, De Bonis M, Dimopoulos K, Donal E, Drexel H, Flachskampf FA, Hall R, Halvorsen S, Hoen B, Kirchhof P, Lainscak M, Leite-Moreira AF, Lip GY, Mestres CA, Piepoli MF, Punjabi PP, Rapezzi C, Rosenhek R, Siebens K, Tamargo J, Walker DM. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015 Nov;36(44):3075-128. DOI: 10.1093/eurheartj/ehv319 External link
30.
Evangelista A, Gonzalez-Alujas MT. Echocardiography in infective endocarditis. Heart. 2004; 90(6):614-7. DOI: 10.1136/hrt.2003.029868 External link
31.
Vilacosta I, Olmos C, de Agustín A, López J, Islas F, Sarriá C, Ferrera C, Ortiz-Bautista C, Sánchez-Enrique C, Vivas D, San Román A. The diagnostic ability of echocardiography for infective endocarditis and its associated complications. Expert Rev Cardiovasc Ther. 2015 Nov;13(11):1225-36. DOI: 10.1586/14779072.2015.1096780 External link
32.
Mügge A. Echocardiographic detection of cardiac valve vegetations and prognostic implications. Infect Dis Clin North Am. 1993 Dec;7(4):877-98.
33.
Misfeld M, Girrbach F, Etz CD, Binner C, Aspern KV, Dohmen PM, Davierwala P, Pfannmueller B, Borger MA, Mohr FW. Surgery for infective endocarditis complicated by cerebral embolism: a consecutive series of 375 patients. J Thorac Cardiovasc Surg. 2014;147(6):1837-44. DOI: 10.1016/j.jtcvs.2013.10.076 External link